A phase III trial published last year showed that dabrafenib combined with trametinib in patients with metastatic disease was superior to
dabrafenib alone, in terms of progression - free survival (22 % vs 12 % at 3 years; hazard ratio [HR], 0.71) and overall survival (44 % vs 32 % at 3 years; HR, 0.75).
Researchers will continue to follow patients on this trial to determine if
dabrafenib alone or dabrafenib given in combination with trametinib is more effective long term.
Initial data shows that
both dabrafenib alone and combined dabrafenib / trametinib therapy are well tolerated by patients, resulting in a 50 to 54 percent response rate among the patients advanced BRAF - mutated papillary thyroid cancer participating in the trial.
Not exact matches
In a randomized, phase 2 multi-center clinical study, led by Manisha Shah, MD of The Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James), investigators tested the effectiveness of the targeted therapy drug,
dabrafenib (pronounced «da bRAF e nib» and marketed as Tafinlar), given
alone compared with the same drug given in combination with trametinib (pronounced «tra ME ti nib,» marketed at MeKinist) to treat a subset of advanced papillary thyroid cancer patients with B - raf mutations.